Elanco Animal Health (NYSE:ELAN) Shares Down 5.8% After Insider Selling

Elanco Animal Health Incorporated (NYSE:ELAN) shares traded down 5.8% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $22.50 and last traded at $22.1210. Approximately 879,071 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 5,584,529 shares. The stock had previously closed at $23.49.

Specifically, insider Timothy Bettington sold 4,350 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.00, for a total value of $100,050.00. Following the completion of the transaction, the insider owned 138,911 shares of the company’s stock, valued at approximately $3,194,953. This represents a 3.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $24.00 target price (down from $31.00) on shares of Elanco Animal Health in a research report on Tuesday. Morgan Stanley increased their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Finally, Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.42.

Elanco Animal Health Trading Down 3.9%

The business’s 50 day moving average is $23.25 and its two-hundred day moving average is $23.58. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $11.28 billion, a P/E ratio of -54.91, a PEG ratio of 1.68 and a beta of 1.70.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period last year, the company posted $0.26 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts expect that Elanco Animal Health Incorporated will post 1.13 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds have recently added to or reduced their stakes in the company. Counterpoint Mutual Funds LLC bought a new position in shares of Elanco Animal Health in the 3rd quarter valued at approximately $601,000. Mitchell & Pahl Private Wealth LLC boosted its stake in Elanco Animal Health by 5.1% during the 3rd quarter. Mitchell & Pahl Private Wealth LLC now owns 53,938 shares of the company’s stock valued at $1,208,000 after purchasing an additional 2,624 shares during the period. NorthCrest Asset Manangement LLC acquired a new stake in Elanco Animal Health in the 3rd quarter valued at approximately $290,000. Wedmont Private Capital increased its holdings in shares of Elanco Animal Health by 38.0% during the 3rd quarter. Wedmont Private Capital now owns 12,948 shares of the company’s stock worth $292,000 after purchasing an additional 3,564 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Elanco Animal Health by 14.1% in the 3rd quarter. GAMMA Investing LLC now owns 14,199 shares of the company’s stock worth $318,000 after acquiring an additional 1,750 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.